What we do Hindustan Bio Sciences Ltd manufactures and markets a diversified range of pharmaceutical products including injectables, syrups, and capsules with global regulatory approvals. |
Founded in 1,991 |
Market share Niche player in pharmaceutical formulations with trusted global presence primarily in finished dosage forms. |
Problem solved Provides high-quality pharmaceutical products addressing healthcare needs in nephrology and other therapeutic areas. |
Top clients or who we serve Serves healthcare professionals and patients worldwide, focusing on pharmaceutical markets (B2B and B2C). |
Key management Venkata Rama Mohan Raju Jampana (Managing Director) with extensive pharma experience. |
Our journey and innovations Transitioned from cement to biotechnology and pharma since 1991, launched key nephrology drug 'EPOVIN' in 2007; owns world-class manufacturing units. |
Where we operate Operates primarily in India with export capabilities globally. |
Top products or what we offer Finished dosage forms including injectables, dry/liquid syrups, eye/ear/nasal drops, pre-filled syringes, ointments, tablets and capsules with DCGI approval. |
Top brands EPOVIN - Recombinant Human Erythropoietin, marketed since 2007, trusted nephrology product. |
Raw materials needed Bulk drugs (APIs) and drug intermediates sourced globally from multiple suppliers. |
Raw materials supplier Global network of suppliers and associates providing high-quality APIs and intermediates. |
Recurring vs cyclical contribution Revenue primarily from recurring sales of pharmaceutical products. |
Our industry position Established niche pharma manufacturer with increasing profitability and regulatory approvals. |
Financial highlights FY 2024-25 Revenue Rs.81.33 Lakhs; Net Profit Rs.10.07 Lakhs; Growth in profit over previous year despite revenue dip. |
Geographical revenue split Majority revenue from India with export revenue contributing a small percentage. |
Order book - |
Whats driving growth Increased demand, regulatory approvals, and expansion in finished dosage pharmaceutical products. |
Our future plans Focus on scaling manufacturing, product portfolio expansion, and maintaining regulatory compliance. |
Our green promise Committed to pollution control and environmentally responsible manufacturing practices. |
Our people and values Emphasizes employee involvement, compliance, and ethical business conduct. |
Key challenges ahead Competitive pharmaceutical market, regulatory complexities, and raw material sourcing risks. |
Interesting facts Originally a cement company, transformed fully into a pharmaceutical and biotech firm since 1991. |
Risks and strategy Mitigates regulatory and market risks via strict compliance, quality focus, and broad supplier base. |
